Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04190823 | A Study of RC98 in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 | 63 | RemeGen Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT04894825 | Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China | unknown | Phase 1 | 152 | FutureGen Biopharmaceutical (Beijing) Co., LtdINDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT05101265 | Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment | unknown | Phase 1 | 24 | PharmaMarINDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT06126705 | 18F-AlF-FAPi-04 PET/CT Imaging in Patients With Solid Tumor | unknown | Early Phase 1 | 60 | Affiliated Hospital of North Sichuan Medical CollegeOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05681000 | Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors | unknown | Phase 1 | 28 | Biostar Pharma, Inc.INDUSTRY | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06116240 | A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors | unknown | Phase 1 | 135 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06011291 | A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer | unknown | Phase 1 | 73 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 27, 2023 | clinicaltrials |
| NCT06004713 | Registry Study in MSI/dMMR Solid Tumors | unknown | — | 190 | Peking University Cancer Hospital & InstituteOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT05716919 | Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule | unknown | Phase 1 | 32 | Machaon Biotherapeutics, Inc.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06056323 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 71 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06092268 | A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 270 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 0 | Oct 23, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT03129139 | A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors(Minnelide 101) | unknown | Phase 1 | 66 | Minneamrita Therapeutics LLCINDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05263180 | A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | unknown | Phase 1 | 30 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Oct 18, 2023 | clinicaltrials |
| NCT06082557 | A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 62 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT06082570 | A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 62 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT06078670 | PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 96 | Fujian Cancer HospitalOTHER_GOV | 0 | Oct 12, 2023 | clinicaltrials |
| NCT06078800 | A Study of YL-17231 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 80 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06065592 | Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms(CAT_PB) | unknown | Phase 1 | 500 | Lebanese UniversityOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT04717674 | [18F]FPIA PET/CT Imaging in Patients With Solid Tumours([18F]FPIA) | unknown | Phase 2 | 21 | University College, LondonOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT03382340 | IMX-110 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 70 | Immix Biopharma Australia Pty LtdINDUSTRY | 2 | Sep 28, 2023 | clinicaltrials |
| NCT05267899 | A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 24 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06054932 | Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors | unknown | Phase 1 | 18 | Beijing Likang Life Science and Tech Co., Ltd.INDUSTRY | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05781386 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors | unknown | Phase 1 | 255 | Jiangsu Simcere Biologics Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06047431 | A Study of QL1706H in Patients With Advanced Solid Tumors | unknown | Phase 1 | 150 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
| NCT06047860 | A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer | unknown | Phase 2 | 30 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06041035 | A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 115 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT06008366 | A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 281 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06008379 | A Study of 7MW3711 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 164 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06030869 | MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors | unknown | — | 400 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06027346 | A Study of Bio-008 in Subjects With Advanced or Metastatic Solid Tumours | unknown | Phase 1 | 60 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05296772 | Phase 1 First-in-human Study of JS014 | unknown | Phase 1 | 60 | Anwita BiosciencesINDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
| NCT04126590 | Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors | unknown | Phase 1 | 39 | Changchun Intellicrown Pharmaceutical Co. LTDINDUSTRY | 1 | Sep 1, 2023 | clinicaltrials |
| NCT06006793 | A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation | unknown | Phase 1 | 50 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT06022276 | Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors | unknown | N/A | 46 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT06022289 | Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors | unknown | Phase 2 | 20 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT06019013 | A Study of QLF3108 in Participants With Advanced Solid Tumor | unknown | Phase 1 | 78 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 31, 2023 | clinicaltrials |
| NCT06015269 | Exploratory Study on Baize DC Injection in Preventing Recurrence and Metastasis After Radical Tumor Surgery | unknown | Phase 1 | 200 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05767684 | Neoantigen Derived DCs as Cancer Treatment | unknown | Phase 1 | 12 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT05982080 | A Study to Investigate FP002 in Subjects With Advanced Malignancies | unknown | Phase 1 | 27 | Guangdong Fapon Biopharma Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT06009835 | DOTr/DOTa Algorithm Guidance for Refractory Solid Tumors | unknown | — | 15 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT05420545 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | unknown | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05468190 | A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T | unknown | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05509985 | A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 100 | AskGene Pharma, Inc.INDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05986981 | MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04965220 | HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors | unknown | Phase 1 | 220 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05840835 | Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors(IMMINENT-01) | unknown | Phase 1 / Phase 2 | 60 | Immix Biopharma, Inc.INDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05976906 | Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors | unknown | Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05971576 | A Clinical Study on TILs for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 2, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 27, 2023source: clinicaltrials